The primary objective of this retrospective study was to investigate the possibility of achieving partial remission (PR) in AS patients treated with anti-TNF-α antagonists, such as adalimumab (ADA), etanercept (ETA) and infliximab (INF), in a real clinical practice setting. Predictors of PR were also evaluated.

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study / Spadaro, Antonio; Lubrano, Ennio; Marchesoni, Antonio; D'Angelo, Salvatore; Ramonda, Roberta; Addimanda, Olga; Perrotta, Fabio Massimo; Olivieri, Ignazio; Punzi, Leonardo; Salvarani, Carlo. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 52:(2013), pp. 1914-1919. [10.1093/rheumatology/ket249]

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study

SALVARANI, CARLO
2013

Abstract

The primary objective of this retrospective study was to investigate the possibility of achieving partial remission (PR) in AS patients treated with anti-TNF-α antagonists, such as adalimumab (ADA), etanercept (ETA) and infliximab (INF), in a real clinical practice setting. Predictors of PR were also evaluated.
52
1914
1919
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study / Spadaro, Antonio; Lubrano, Ennio; Marchesoni, Antonio; D'Angelo, Salvatore; Ramonda, Roberta; Addimanda, Olga; Perrotta, Fabio Massimo; Olivieri, Ignazio; Punzi, Leonardo; Salvarani, Carlo. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 52:(2013), pp. 1914-1919. [10.1093/rheumatology/ket249]
Spadaro, Antonio; Lubrano, Ennio; Marchesoni, Antonio; D'Angelo, Salvatore; Ramonda, Roberta; Addimanda, Olga; Perrotta, Fabio Massimo; Olivieri, Ignazio; Punzi, Leonardo; Salvarani, Carlo
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1078874
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 55
social impact